Safety evaluation of high-dose vitamin B6 injection in clinical application: a single center, retrospective study based on real-world data

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300072496

Enrollment

Unknown

Registered

2023-06-15

Start date

2023-04-01

Completion date

Unknown

Last updated

2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

VB6 security

Interventions

High-dose VB6 group(Daily dose = 3g):N/A

Low-dose VB6 group(Daily dose =0.5g):N/A

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. All inpatients who have used VB6; 2. Age: 18 years old; 3. =3 days, =60 days in hospital; 4. A single dose of VB6 was used during hospitalization and used for =3 days; 5. At least one test of biochemical indicators related to liver and kidney function before using VB6, and all of them were below the high limit of the normal reference value range; 6. At least one liver and kidney function after 3 days after consecutive use of VB 6 .

Exclusion criteria

Exclusion criteria: Patients treated in the intensive care (ICU), oncology, or nephrology departments

Design outcomes

Primary

Measure	Time frame
Glutamyl aminotransferase;alanine transaminase;aspartate aminotransferase;blood creatinine;alkaline phosphatase;	—

Countries

China

Contacts

Public Contactyinjinnan

Changzhou Wujin People's Hospital

qinhongzmc@163.com+86 139 6129 6010

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026